Analysis of melanoma patients who developed BRAF inhibitor resistance revealed increased mitogen-activated protein kinase signaling from either development of NRAS and KRAS mutations in progressive tumors, or through 2- to 15-fold increase in BRAF mRNA compared with patient-matched baseline tumors (40). This evidence concerns the gene KRAS and melanoma.